Pharming Group N.V. (PHAR) Total Current Liabilities (2019 - 2024)

Pharming (PHAR) has disclosed Total Current Liabilities for 6 consecutive years, with $73.8 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Current Liabilities fell 5.34% year-over-year to $73.8 million, compared with a TTM value of $73.8 million through Dec 2024, down 5.34%, and an annual FY2024 reading of $73.8 million, down 5.34% over the prior year.
  • Total Current Liabilities was $73.8 million for Q4 2024 at Pharming, down from $78.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $78.0 million in Q4 2023 and bottomed at $46.8 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $66.6 million, with a median of $73.8 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities crashed 37.31% in 2021, then soared 30.6% in 2023.
  • Year by year, Total Current Liabilities stood at $74.6 million in 2020, then crashed by 37.31% to $46.8 million in 2021, then grew by 27.64% to $59.7 million in 2022, then surged by 30.6% to $78.0 million in 2023, then fell by 5.34% to $73.8 million in 2024.
  • Business Quant data shows Total Current Liabilities for PHAR at $73.8 million in Q4 2024, $78.0 million in Q4 2023, and $59.7 million in Q4 2022.